Skip to content

Original explainers & special topics from Nakitte

Nakitte Featured

Plain-English explainers and deep-dives on the topics behind the headlines — written by Nakitte, for investors who want the context, not just the ticker.

Explainer — The AI Anxiety Paradox: Workers Most Fearful of Job Loss Are Upskilling, Demanding Raises and Spending More
📘 ExplainerJuly 2, 2026

The AI Anxiety Paradox: Workers Most Fearful of Job Loss Are Upskilling, Demanding Raises and Spending More

For years, the dominant narrative around artificial intelligence has been one of looming displacement. Headlines have warned of mass job losses, with estimates ranging from Goldman Sachs’ projection of up to 300 million full-time equivalent roles exposed globally to the IMF’s assessment that roughly 40% of jobs worldwide — and 60% in advanced economies — are exposed to AI.

Nakitte Featured7 min
Explainer — Germany’s Automotive Powerhouse Faces Existential Test: Can Restructuring and Policy Reforms Restore Competitiveness?
📘 ExplainerJune 27, 2026

Germany’s Automotive Powerhouse Faces Existential Test: Can Restructuring and Policy Reforms Restore Competitiveness?

The German automotive industry, long a pillar of Europe’s industrial might and a symbol of engineering excellence, is navigating one of its most severe crises in decades. In 2025 and into 2026, the sector has recorded sharp profit declines, accelerated job losses, and a dramatic erosion of its dominant position in key export markets

Nakitte Featured6 min
Explainer — Inspecting Data-Center-Specific Energy Solutions: How Vertiv, Schneider Electric, Bloom Energy and Constellation Address High-Density AI Power and Thermal Challenges
📘 ExplainerJune 23, 2026

Inspecting Data-Center-Specific Energy Solutions: How Vertiv, Schneider Electric, Bloom Energy and Constellation Address High-Density AI Power and Thermal Challenges

AI and high-performance computing workloads have pushed server and rack heat densities far beyond traditional air-cooling limits. Modern GPU-heavy racks now exceed 80–100 kW, with individual servers generating heat loads of 6–10 kW or more—up to 50× the thermal output of legacy CPUs in some accelerator configurations.

Nakitte Featured9 min
Macro — ASML, Chinese EVs, and the Battery Trap: Is Europe’s Green Dream Turning into a Deindustrialization Nightmare?
🌐 MacroJune 11, 2026

ASML, Chinese EVs, and the Battery Trap: Is Europe’s Green Dream Turning into a Deindustrialization Nightmare?

Europe’s automotive heartland is under siege. In 2025, the continent’s vehicle production remained 15-20% below pre-pandemic levels, with capacity utilization hovering around 55% at many plants. Tens of thousands of jobs have already vanished—90,000 in the auto sector in 2024 alone—with forecasts of hundreds of thousands more at risk in manufacturing and supply chains.

Nakitte Featured10 min
Explainer — Energiewende at the Crossroads: Germany's Energy Transition Amid Geopolitical Shocks and Shifting Global Energy Politics
📘 ExplainerJune 9, 2026

Energiewende at the Crossroads: Germany's Energy Transition Amid Geopolitical Shocks and Shifting Global Energy Politics

Germany’s Energiewende (energy transition) stands as one of the most ambitious national decarbonization efforts in history. Launched with deep roots in the environmental movements of the 1970s and accelerated through landmark legislation in the 2000s and 2010s, it has delivered remarkable growth in renewable electricity while driving substantial greenhouse gas reductions.

Nakitte Featured8 min
Explainer — AI Drug Discovery: Early Clinical Wins Signal a Credible Path to Counter Pharma’s Productivity Crisis and Ease Long-Term Healthcare Cost Pressures
📘 ExplainerJune 8, 2026

AI Drug Discovery: Early Clinical Wins Signal a Credible Path to Counter Pharma’s Productivity Crisis and Ease Long-Term Healthcare Cost Pressures

When Insilico Medicine announced in November 2024 that its generative AI-designed TNIK inhibitor, Rentosertib (formerly ISM001-055), produced dose-dependent improvements in forced vital capacity for idiopathic pulmonary fibrosis patients in a Phase IIa trial—with a +98.4 mL mean gain at the highest dose versus a -62.3 mL decline on placebo—the result carried weight far beyond one disease area.

Nakitte Featured9 min